Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 51 - 100 av 103 resultater
Tid
Selskap
Tittel
Sektor
Kategori
31 Oct 2019
18:00 CET
ATON
Hybrigenics : report de la publication des comptes semestriels 2019
Biotechnology
Income
15 Oct 2019
17:59 CEST
ATON
Prise de contrôle d’Hybrigenics : DMS Group détient 80% du capital d’Hybrigenics et Hybrigenics détient 100% de DMS Biotech
Biotechnology
Mergers, Acquiqitions, Transferts
09 Oct 2019
18:00 CEST
ATON
Prise de contrôle d’Hybrigenics par DMS : obtention de la dérogation de l’AMF
Biotechnology
Takeover bids
20 Sep 2019
17:00 CEST
ATON
Assemblée générale mixte d’Hybrigenics du 20 septembre 2019 : approbation de toutes les résolutions
Biotechnology
General meeting / Board Meeting
19 Sep 2019
18:00 CEST
ATON
Assemblée générale mixte d’Hybrigenics du 20 septembre 2019 : quorum atteint
Biotechnology
General meeting / Board Meeting
29 Jul 2019
18:00 CEST
ATON
Hybrigenics : convocation à une assemblée générale mixte le 6 septembre 2019
Biotechnology
General meeting / Board Meeting
20 Jun 2019
18:00 CEST
ATON
Hybrigenics : résultats annuels 2018 et informations sur le projet d’apport partiel d’actifs de DMS Group
Biotechnology
Income
20 Jun 2019
18:00 CEST
ATON
Hybrigenics full year 2018 results and update on the takeover project by DMS Group
Biotechnology
Income
07 Feb 2019
18:02 CET
ATON
DMS Group et Hybrigenics entrent en négociation exclusive
Biotechnology
Corporate life
07 Feb 2019
18:01 CET
ATON
DMS Group and Hybrigenics enter into exclusive negotiation
Biotechnology
Corporate life
14 Jan 2019
08:01 CET
ATON
Hybrigenics reçoit une offre de prise de contrôle
Biotechnology
-
14 Jan 2019
08:00 CET
ATON
Hybrigenics has received a takeover offer
Biotechnology
Other subject
20 Dec 2018
18:00 CET
ATON
Hybrigenics : convocation à une nouvelle assemblée générale mixte le 15 janvier 2019
Biotechnology
-
19 Dec 2018
18:20 CET
ATON
Hybrigenics : réponses aux questions écrites des actionnaires
Biotechnology
-
04 Dec 2018
18:30 CET
ATON
Hybrigenics asks Moonstone Investments to clarify its offer
Biotechnology
-
04 Dec 2018
18:30 CET
ATON
Hybrigenics demande à Moonstone Investments de clarifier son offre
Biotechnology
-
03 Dec 2018
18:00 CET
ATON
Hybrigenics half-year 2018 consolidated accounts set at liquidation value
Biotechnology
-
03 Dec 2018
18:00 CET
ATON
Hybrigenics : comptes consolidés semestriels 2018 établis en valeur de liquidation
Biotechnology
-
23 Oct 2018
17:45 CEST
ATON
Arrêt de l’étude clinique de l’inécalcitol dans la Leucémie Myéloïde Aiguë pour cause de futilité
Biotechnology
-
23 Oct 2018
17:45 CEST
ATON
Clinical study of inecalcitol in acute myeloid leukemia stopped for futility
Biotechnology
-
19 Oct 2018
18:00 CEST
ATON
Hybrigenics asked for trading suspension
Biotechnology
-
19 Oct 2018
18:00 CEST
ATON
Hybrigenics : demande de suspension de cotation
Biotechnology
-
18 Jul 2018
18:00 CEST
ATON
Hybrigenics : fin du recrutement de l’étude clinique internationale de Phase II de l’inécalcitol dans la Leucémie Myéloïde Aiguë
Biotechnology
-
18 Jul 2018
18:00 CEST
ATON
Hybrigenics completes enrolment of the international Phase II clinical study of inecalcitol in Acute Myeloid Leukemia
Biotechnology
-
26 Apr 2018
20:36 CEST
ATON
Hybrigenics : résultats annuels 2017 et informations sur les études cliniques menées avec l’inécalcitol
Biotechnology
-
26 Apr 2018
20:35 CEST
ATON
Hybrigenics full year 2017 results and update on the clinical studies of inecalcitol
Biotechnology
-
26 Mar 2018
18:00 CEST
ATON
Hybrigenics’ broad-spectrum inhibitor of Ubiquitin-Specific Proteases shows antiviral activity against human adenoviruses
Biotechnology
-
26 Mar 2018
18:00 CEST
ATON
L’inhibiteur à spectre large des protéases spécifiques de l’ubiquitine d’Hybrigenics présente une activité antivirale contre les adénovirus humains
Biotechnology
-
19 Feb 2018
08:00 CET
ATON
Hybrigenics completes its strategic refocusing on biopharmaceutical R&D
Biotechnology
-
19 Feb 2018
08:00 CET
ATON
Hybrigenics parachève son recentrage stratégique sur la R&D biopharmaceutique
Biotechnology
-
11 Dec 2017
08:00 CET
ATON
Hybrigenics présente au congrès annuel de l’ASH la puissance de l’inécalcitol pour stimuler le CD38 sur des lignées de Myélome Multiple
Biotechnology
-
11 Dec 2017
08:00 CET
ATON
Hybrigenics presented at the ASH Annual Meeting the potency of inecalcitol to induce CD38 on Multiple Myeloma cell lines
Biotechnology
-
26 Oct 2017
19:20 CEST
ATON
Hybrigenics half-year 2017 results
Biotechnology
-
26 Oct 2017
19:20 CEST
ATON
Hybrigenics : résultats du 1er semestre 2017
Biotechnology
-
09 Oct 2017
18:30 CEST
ATON
Un composé d’Hybrigenics inhibe l’Ubiquitin-Specific Protease 10 (USP10) et se montre actif dans des modèles précliniques de Leucémie Myéloïde Aiguë (LMA)
Biotechnology
-
09 Oct 2017
18:30 CEST
ATON
Hybrigenics’ compound inhibits Ubiqitin-Specific Protease 10 (USP10) and shows activity in preclinical models of Acute Myeloid Leukemia (AML)
Biotechnology
-
24 Jul 2017
17:55 CEST
ATON
Succès de l’augmentation de capital d’Hybrigenics qui lève 6,8 M€
Biotechnology
-
30 Jun 2017
08:00 CEST
ATON
Hybrigenics lance une augmentation de capital de 6,8 M€ avec maintien du droit préférentiel de souscription des actionnaires
Biotechnology
-
06 Jun 2017
18:00 CEST
ATON
Hybrigenics reçoit un brevet européen protégeant des inhibiteurs de la protéase spécifique de l’ubiquitine n°8 (USP8)
Biotechnology
-
06 Jun 2017
18:00 CEST
ATON
Hybrigenics gets European patent protection for inhibitors of Ubiquitin-Specific Protease 8 (USP8)
Biotechnology
-
18 May 2017
18:00 CEST
ATON
Hybrigenics’ inhibitor of Ubiquitin-Specific Protease 7 (USP7) shows activity in preclinical models of Chronic Lymphocytic Leukemia (CLL)
Biotechnology
-
18 May 2017
18:00 CEST
ATON
Un inhibiteur d’Ubiquitin-Specific Protease 7 (USP7) d’Hybrigenics est actif dans des modèles précliniques de leucémie lymphoïde chronique (LLC)
Biotechnology
-
28 Apr 2017
18:00 CEST
ATON
Hybrigenics full year 2016 results
Biotechnology
-
28 Apr 2017
18:00 CEST
ATON
Hybrigenics : résultats annuels 2016
Biotechnology
-
03 Apr 2017
07:30 CEST
ATON
Hybrigenics presents new results on the specificity of inecalcitol in acute myeloid leukemia and multiple myeloma at AACR 2017
Biotechnology
-
03 Apr 2017
07:30 CEST
ATON
Hybrigenics présente à l’AACR 2017 de nouveaux résultats sur la spécificté de l’inécalcitol dans la leucémie myéloïde aiguë et le myélome multiple
Biotechnology
-
13 Mar 2017
18:00 CET
ATON
Hybrigenics: strategic refocusing on biopharmaceutical R&D
Biotechnology
-
13 Mar 2017
18:00 CET
ATON
Hybrigenics : recentrage stratégique sur la R&D biopharmaceutique
Biotechnology
-
09 Feb 2017
18:00 CET
ATON
Résultats préliminaires encourageants de l’étude clinique de Phase II de l’inécalcitol dans la Leucémie Myéloïde Chronique
Biotechnology
-
09 Feb 2017
18:00 CET
ATON
Encouraging preliminary results of the Phase II clinical study of inecalcitol in Chronic Myeloid Leukemia
Biotechnology
-
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva